RxDoctor Payments Data

Adam Brown, DPM

Foot & Ankle Surgery · Reseda, CANPI 1629475165

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $5,893 of the $6,594 with a category attached, or 89.4%. 23 manufacturers reported payments, led by Musculoskeletal Transplant Foundation Inc. at 42.5% of the total. Reporting peaked in 2020 at $3,019 and has fallen 65.7% since, to $1,036 in 2025.

$6,594in general payments, 2019–2025

Across 133 payments — averaging $49.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Musculoskeletal Transplant Foundation Inc.$3K
  • Paratek Pharmaceuticals, Inc.$1K
  • Smith+Nephew$809
  • Amgen$519
  • Nevro Corp.$319
  • Melinta Therapeutics, LLC$212
  • plus $765 from 17 others
$45,680in research payments, 2019–2025

Across 9 payments — averaging $5075.56 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Royal Biologics, Inc.$46K

What the payments were for

  • Travel & lodging$70111%
  • Food & beverage$5,89389%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,594 in reported general payments places this provider in the 75th percentile of 1,126 foot & ankle surgery providers in California.

See all foot & ankle surgery providers in California

Medicare billing

Part B allowed, 2024
$270,532
Medicare patients
64
Services billed
1,616

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Clotrimazole61$2,060
Ammonium Lactate80$1,166
Ketoconazole50$638
Oxycodone Hcl17$353
Ciclopirox11$249
Diclofenac Sodium16$177
Triamcinolone Acetonide17$142
Mupirocin24$91
Terbinafine Hcl12$64
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim12$35

Paid to pharmacies, not to this prescriber.

Other foot & ankle surgery in Reseda

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →